Kamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing Laboratory
Globe Newswire (Mon, 1-Jun 7:00 AM ET)
Globe Newswire (Wed, 13-May 7:00 AM ET)
Kamada to Announce First Quarter 2026 Financial Results on May 13, 2026
Globe Newswire (Wed, 6-May 7:00 AM ET)
Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders
Globe Newswire (Tue, 31-Mar 7:00 AM ET)
Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas
Globe Newswire (Thu, 26-Mar 7:00 AM ET)
Market Chameleon (Wed, 7-Jan 3:38 AM ET)
Market Chameleon (Mon, 8-Dec 3:22 AM ET)
Market Chameleon (Mon, 10-Nov 4:11 AM ET)
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
Kamada Ltd. - trades on the NASDAQ stock market under the symbol KMDA.
As of June 15, 2026, KMDA stock price climbed to $7.46 with 18,634 million shares trading.
KMDA has a beta of 0.89, meaning it tends to be less sensitive to market movements. KMDA has a correlation of 0.14 to the broad based SPY ETF.
KMDA has a market cap of $430.30 million. This is considered a Small Cap stock.
Last quarter Kamada Ltd. - reported $45 million in Revenue and $.07 earnings per share. This fell short of revenue expectation by $-79 million and missed earnings estimates by -$.05.
In the last 3 years, KMDA traded as high as $9.35 and as low as $4.08.
The top ETF exchange traded funds that KMDA belongs to (by Net Assets): DISV, DFIS, DFIC, DFAX, IBBQ.
KMDA has underperformed the market in the last year with a price return of +11.1% while the SPY ETF gained +26.2%. KMDA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -11.3% and -4.5%, respectively, while the SPY returned +13.6% and -0.2%, respectively.
KMDA support price is $7.29 and resistance is $7.60 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KMDA shares will trade within this expected range on the day.
